Sekisui Diagnostics announced today that its microbial CDMO business completed construction of a £15.7 million ($20.7 million) drug substance manufacturing capacity expansion. The company completed its cGMP capacity expansion at its U.K. site for clinical-grade drug substance manufacturing. Following appropriate licensure, the expansion can enable manufacturing capabilities for common drug types. Those include enzymes, proteins…